Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may improve CV outcomes in patients with diabetes undergoing cancer therapy. The ...

Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials– This next-generation anthracycline demonstrates safety and promising early activity in treating multiple ...

Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial We evaluated 2,808 echocardiograms in 829 breast cancer ...

The prevalence of subclinical cardiotoxicity identified by echocardiographic global longitudinal strain (GLS) in patients with breast cancer taking doxorubicin (Adriamycin) was similar whether ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS. At the ASPC 2025 Congress ...

Fewer than half of all women with breast cancer treated with chemotherapy are followed up with the recommended cardiac monitoring to help identify left ventricular dysfunction, according to a new, ...

Please provide your email address to receive an email when new articles are posted on . Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor ...

Doxorubicin (Doxo) is a widely used chemotherapeutic drug for cancer, though it can have toxic effects on the heart. A recent animal study investigated whether the cardioregulatory protein ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...